other material
confidence high
sentiment positive
materiality 0.65
Vistagen announces positive Phase 2A results for PH284 in cancer cachexia; 71% hunger improvement
Vistagen Therapeutics, Inc.
- PH284 nasal spray demonstrated 71% improvement in subjective feeling of hunger before dinner on Day 7 vs <1% for placebo.
- No serious adverse events; adverse events similar to placebo and attributed to underlying cancer, not treatment.
- PH284 is fifth pherine product candidate in Vistagen's neuroscience pipeline with a positive efficacy signal.
- Study enrolled 40 female patients with cachexia due to terminal cancer; double-blind, placebo-controlled design.